Economic Impact on Kidney Disease Progression and Outcomes

By HEOR Staff Writer

March 14, 2024

Introduction:

Chronic Kidney Disease (CKD) remains a significant public health concern, affecting an estimated 850 million people globally. With the rapid rise in CKD prevalence and complications, it is projected to become the fifth most common cause of years of life lost by 2040. On world kidney day we look at the socioeconomic factors influencing CKD progression and the potential of AI in predicting acute kidney disease outcomes.

The Socioeconomic Impact on CKD Progression:

Despite the attention given to socioeconomic status in relation to CKD development and progression, health disparities associated with socioeconomic factors have not reduced worldwide. Even in countries with universal health coverage, income-related disparities associated with CKD are prevalent. Lower income levels are associated with faster CKD progression and a higher risk of initiation of Kidney Replacement Therapies (KRTs). This finding provides crucial information for future health care policies, highlighting the need for more active support beyond financial assistance.

Factors and CKD in Japan:

A recent study in Japan, a country with universal health coverage, found a strong association between lower income levels and faster progression of CKD. These lower income individuals also had a higher risk of starting KRT. The disparities in rapid CKD progression and initiation of KRT across income levels were significant. This occurred despite the country’s comprehensive healthcare coverage and minimal financial obstacles to medical services. These findings suggest that income disparity relates not only to financial barriers to medical care, but also to factors such as health literacy, psychosocial stress, and stress-related behavioural risks.

Key Findings from the Japanese Study:

The study revealed that the risk for the lower income group was over 60% higher than that of the highest income group. This was the case even in a country with almost universal health coverage. They observed this negative monotonic association more prominently among males and those without diabetes. These findings indicate a need to target socioeconomically disadvantaged populations. They underscore the importance of interventions across society to minimise social and behavioural risks for low-income individuals.

The Role of AI in Predicting AKI Outcomes:

Acute Kidney Injury (AKI) complicates 13–18% of hospital admissions in the UK. Predicting which inpatient cases progress to require Renal Replacement Therapy (RRT) remains an unaddressed challenge. Recent research has shown the potential of a Recurrent Neural Network (RNN) in predicting AKI. This AI tool could predict AKI up to 48 hours in advance, the risk of an inpatient with AKI requiring RRT therefore being admitted to a hospital or dying.

Conclusion:

In conclusion, there is a substantial association between low-income levels and the development of impaired kidney function. Moreover, this is seen with rapid CKD progression and initiation of KRT. The findings highlight the importance of society-wide interventions aimed at reducing the social and behavioural risks to individuals in the low-income group. Furthermore, AI has shown promise in predicting AKI progression. If this becomes validated, it could improve patient care while streamlining healthcare resource allocation.

Reference url

Recent Posts

NICE Kidney Cancer Guideline: Enhancing Biopsy Use to Minimize Unnecessary Surgery

By João L. Carapinha

September 18, 2025

The NICE kidney cancer guideline represents a major shift in how renal cell carcinoma is diagnosed and managed in the UK. How does this guideline change the standard of kidney cancer care? By emphasizing more accurate diagnosis—especially the targeted use of kidney biopsies—it aims to avoid unnec...
CAPVAXIVE Pneumococcal Vaccine Delivers Strong Immune Response in At-Risk Youth

By HEOR Staff Writer

September 17, 2025

What makes the CAPVAXIVE pneumococcal vaccine significant for children and adolescents at higher risk for pneumococcal disease? The CAPVAXIVE pneumococcal vaccine (21-valent conjugate vaccine) demonstrated robust immune responses and broad serotype coverage in Merck’s Phase 3 STRIDE-13 trial. ...
Oral Semaglutide Benefits: EMA Approves First Oral GLP-1 RA with Cardiovascular Perks

By HEOR Staff Writer

September 16, 2025

Novo Nordisk’s oral semaglutide (Rybelsus®) has received a significant label update from the European Medicines Agency (EMA). It is now the first and only oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved in the EU for type 2 diabetes with proven cardiovascular benefits. This deci...